Monkey-Derived Circular Peptides Killed Drug-Resistant Candida Fungi 200 Times More Effectively Than Human Saliva Peptides

Researchers tested the antifungal activity of RTD-1 and 13 other natural theta-defensin isoforms against drug-sensitive and multidrug-resistant clinical isolates of Candida albicans and non-albicans species using MIC/MFC assays. They characterized the killing mechanism through cell permeabilization, ATP release, and ROS accumulation assays. They compared RTD-1's potency and speed of killing to histatin 5, assessed protease resistance against Candida enzymes, and benchmarked activity against amphotericin B and caspofungin.

Candida auris and other multidrug-resistant fungi are classified as urgent threats by the CDC, and the current antifungal drug arsenal is extremely limited — only three major drug classes exist. Finding new antifungal agents is arguably even more urgent than finding new antibiotics. Theta-defensins are remarkable because their circular (macrocyclic) structure makes them inherently resistant to enzyme degradation — one of the biggest barriers to peptide drug development. Their activity against C. auris at concentrations outperforming standard-of-care drugs makes them compelling templates for new antifungal therapeutics.

Theta-defensins are unique among antimicrobial peptides because they are the only known cyclic defensins in mammals. Humans actually carry the genes for theta-defensins but can't produce them due to a premature stop codon — a quirk of primate evolution. This study demonstrates that what monkeys naturally produce could be exactly what humans need to fight drug-resistant fungi. The macrocyclic structure that gives theta-defensins their protease resistance is now a major design principle in peptide drug development more broadly, with stapled and cyclic peptides becoming increasingly important across oncology, metabolic disease, and infectious disease.

This was an in vitro (lab dish) study — no animal infection models or human data were included. While the peptides outperformed existing drugs in killing assays, real-world antifungal therapy involves pharmacokinetics, tissue distribution, toxicity, and host immune interactions that weren't assessed. The comparison with histatin 5 is informative but somewhat unfair — Hst 5 evolved for saliva, not systemic use. Manufacturing costs for macrocyclic peptides can be high. Whether fungal pathogens could develop resistance to theta-defensins over time is unknown.